Je was op zoek naar: prophylaxis (Fins - Engels)

prophylaxis of influenza
influenza

altistusta edeltävä estohoito (pre-exposure prophylaxis, prep):
pre-exposure prophylaxis (prep):

l04 a1 prophylaxis of acute organ rejection in the novorenal transplantation
g04b e erectile dysfunction

l04aa10 prophylaxis of organ rejection in patient receiving renal transplants
l04aa10 rophylaxis of organ rejection in patient receiving renal transplants

l04a prophylaxis of acute organ rejection in patients receiving renal transplants
l04a prophylaxis of acute rejection in renal transplantation

j05ah02 treatment of influenza and post-exposure prophylaxis of influenza l03ab11 treatment of chronic hepatitis c in adults
· l03ab11 · treatment of chronic hepatitis c in adults

emea/mb/050 vuosikertomus 2000 sivu 81/85 note for guidance on the clinical emea/cpmp/bpwg/198/95 toimitettu lausuntoa varten investigation of human plasma derived rev.1 kesäkuussa 2000 factor viii and ix products note for guidance on the clinical toimitettu lausuntoa varten emea/cpmp/bpwg/1561/99 investigation of recombinant factor viii kesäkuussa 2000 and ix products emea/cpmp/phvwp/bpwg/toimitettu lausuntoa varten core spc for human albumin 2231/99 kesäkuussa 2000 note for guidance on the clinical toimitettu lausuntoa varten emea/cpmp/bpwg/2220/99 investigation of plasma derived joulukuussa 2000 antithrombin products core spc for human plasma derived toimitettu lausuntoa varten emea/cpmp/bpwg/3226/99 antithrombin joulukuussa 2000 cpmp: n tehokkuustyöryhmä viitenumero ohje tilanne note for guidance on clinical investigation emea/cpmp/ewp/519/98 hyväksytty helmikuussa 2000 of steroid contraceptives in woman points to consider concerning endpoints in clinical studies with haematopoietic growth emea/cpmp/ewp/197/99 hyväksytty helmikuussa 2000 factors for mobilisation of autologous stem cells points to consider on the clinical investigation of new medicinal products for emea/cpmp/ewp/570/98 treatment of acute coronary syndrome hyväksytty helmikuussa 2000 (acs) without persistent st-segment elevation concept paper on the development of a cpmp note for guidance on the clinical emea/cpmp/ewp/2922/99 hyväksytty helmikuussa 2000 investigation of medicinal products in the treatment of asthma concept paper on the development of a cpmp points to consider on biostatistical/methodological issues arising emea/cpmp/ewp/2863/99 hyväksytty helmikuussa 2000 from cpmp discussions on licensing applications: adjustment for baseline covariates points to consider on clinical investigation of medicinal products for prophylaxis of emea/cpmp/ewp/707/98 hyväksytty kesäkuussa 2000 intra -and post-operative venous thromboembolic risk concept paper on the development of a cpmp note for guidance on the clinical emea/cpmp/ewp/612/00 hyväksytty kesäkuussa 2000 investigation of medicinal products in pain management points to consider on pharmaco-kinetics emea/cpmp/ewp/2655/99 and pharmacodynamics in the development hyväksytty heinäkuussa 2000 of anti-bacterial medicinal products points to consider on switching between emea/cpmp/ewp/482/99 hyväksytty heinäkuussa 2000 superiority and non-inferiority concept paper on the development of a cpmp note for guidance on clinical emea/cpmp/ewp/1080/00 hyväksytty heinäkuussa 2000 investigation of medicinal products in the treatment of diabetes mellitus points to consider on clinical investigation emea/cpmp/ewp/565/98 of medicinal products for treatment of hyväksytty lokakuussa 2000 amyotrophic lateral sclerosis (als) concept paper on the evaluation of drugs emea/cpmp/ewp/785/97 for the treatment of the irritable bowel hyväksytty marraskuussa 2000 syndrome note for guidance on clinical investigation emea/cpmp/ewp/566/98 rev.
guidelines/status note for guidance on clinical investigation of steroid contraceptives in woman adopted february 2000 points to consider concerning endpoints in clinical studies with haematopoietic growth factors for mobilisation of autologous stem cells adopted february 2000 points to consider on the clinical investigation of new medicinal products for treatment of acute coronary syndrome (acs) without persistent st-segment elevation adopted february 2000 concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in the treatment of asthma adopted february 2000 concept paper on the development of a cpmp points to consider on biostatistical/methodological issues arising from cpmp discussions on licensing applications: adjustment for baseline covariates adopted february 2000 points to consider on clinical investigation of medicinal products for prophylaxis of intra-and post-operative venous thromboembolic risk adopted june 2000 concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in pain management adopted june 2000 points to consider on pharmaco-kinetics and pharmacodynamics in the development of anti-bacterial medicinal products adopted july 2000 points to consider on switching between superiority and non-inferiority adopted july 2000 concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus adopted july 2000 points to consider on clinical investigation of medicinal products for treatment of amyotrophic lateral sclerosis (als) adopted october 2000 concept paper on the evaluation of drugs for the treatment of the irritable bowel syndrome adopted november 2000 note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders adopted in november 2000 points to consider on clinical investigation of medicinal products for the management of crohn 's disease released for consultation july 200085emea/cpmp/epw/205/95 rev.1emea/cpmp/ewp/560/98emea/cpmp/ewp/2330/99emea/cpmp/ewp/1119/98 emea/cpmp/ewp/714/98emea/cpmp/ewp/qwp/1401/98 emea/cpmp/ewp/2747/00note for guidance on evaluation of anticancer medicinal products in man released for consultation july 2000 and extended in september 2000 for a further 2 months points to consider on clinical investigation of medicinal products in the treatment of acute stroke released for consultation october 2000 points to consider on validity and interpretation of meta-analyses, and one pivotal study released for consultation october 2000 points to consider on the evaluation of diagnostic agents released for consultation november 2000 note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease released for consultation november 2000 note for guidance on the investigation of bioavailability and bioequivalence released for consultation december 2000 note for guidance on co-ordinating investigator signature of clinical study reports released for consultation december 2000